OncoSec Reports Result of Keytruda + TAVO in P-II KEYNOTE-890 Study for Refractory Metastatic Triple Negative Breast Cancer

OncoSec Reports Result of Keytruda + TAVO in P-II KEYNOTE-890 Study for Refractory Metastatic Triple Negative Breast Cancer

Shots:

  • The P-II KEYNOTE-890 study results involve assessing of Keytruda (200mg, IV) + TAVO (tavokinogene telseplasmid) in 25 patients with heavily pretreated, CT/radiotherapy refractory mTNBC who failed an average of 3.5 prior lines of CT
  • The P-II KEYNOTE-890 study result:  @3mos. 20% + tumor reduction; two patients showed 66% tumor reduction including reduction of liver lesions; well tolerated
  • OncoSec’s TAVO (tavokinogene telseplasmid) is an immunotherapy platform, allowing the intratumoral delivery of IL-12 and Keytruda (pembrolizumab) is mAb targeting PD-1, blocking the interaction b/w PD-1 and its ligands, PD-L1 and PD-L2 thus activating T-lymphocytes affecting both tumor & healthy cells

Click here to read full press release/ article | Ref: OncoSec | Image: OncoSec Medical Incorporated (ONCS)